Favorable Long-Term Results With Ranibizumab Implant for Neovascular AMD

(MedPage Today) -- The ranibizumab port delivery system (PDS; Susvimo) with 6-month refill maintained noninferiority to monthly intravitreal injections for neovascular age-related macular degeneration (nAMD) out to 2 years, according to updated...
Source: MedPage Today Public Health - Category: American Health Source Type: news